U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H7N.2Cl.Pt.H3N
Molecular Weight 376.147
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PICOPLATIN

SMILES

N.[Cl-].[Cl-].[Pt++].CC1=CC=CC=N1

InChI

InChIKey=IIMIOEBMYPRQGU-UHFFFAOYSA-L
InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H7N
Molecular Weight 93.1265
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H3N
Molecular Weight 17.0305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Picoplatin is a sterically hindered platinum (II) complex with antineoplastic properties developed for the treatment of cis-platin-resistant cancer. Picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis. However, in Phase III trials, picoplatin failed to meet its primary endpoint for advanced cell lung cancer. It remains in development for other cancers.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
81
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCT1
327

OCT3
80

OCT2
355

MRP1
107
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OCT3
80
 no [IC50 3.2 uM]
MRP1
107
 no
OCT2
355
 yes [IC50 0.277 uM]
OCT1
327
 yes [IC50 0.44 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA0022XE
https://www.aablocks.com/goods/Goods/detail?id=AA0022XE
ABI Chem
AC1L42P3
AN PharmaTech
AN-30599
Aaron Chemicals
AR0023P6
http://www.aaronchem.com/181630-15-9
Adooq BioScience
A14108
https://www.adooq.com/picoplatin.html
BioSynth
J-011604
https://www.biosynth.com/en/products/all-products/products/J-011604.html
ChemMol
49420136
http://www.chemmol.com/chemmol/49420136.html
MolPort
MolPort-006-170-014
https://www.molport.com/shop/molecule-link/MolPort-006-170-014
NovoSeek
177358
eNovation Chemicals
Y1054892
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1054892
iChemical
EBD36764
http://www.ichemical.com/chemicals/cas-181630-15-9
PubMed

PubMed

TitleDatePubMed
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
1998
ZD-0473 AstraZeneca.
2000 Oct
Patents

Patents

0123121
1
8168661
1
8168662
1
8173686
1
8178564
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Dosing from failed Phase III clinical trial.
In a clinical trial, picoplatin was administered intravenously at a dose of 150 mg/m2 every 3 weeks.
Route of Administration: Intravenous
In Vitro Use Guide
In a growth inhibition assay, ovarian carcinoma cell lines were treated serial dilutions of picoplatin for 96 h. Among the cell lines, the drug demonstrated a mean IC50 value of 8.1 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:59:59 UTC 2023
Edited
by admin
on Sat Dec 16 16:59:59 UTC 2023
Record UNII
B5TAN0L720
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PICOPLATIN
INN   MART.   MI   USAN  
INN   USAN  
Official Name English
AMD473
Code English
NX473
Code English
PLATINUM, AMMINEDICHLORO(2-METHYLPYRIDINE)-, (SP-4-3)-
Common Name English
Picoplatin [WHO-DD]
Common Name English
(SP-4-3)-Amminedichloro(2-methylpyridine)platinium
Common Name English
PICOPLATIN [MART.]
Common Name English
AMD-473
Code English
PICOPLATIN [USAN]
Common Name English
ZD-0473
Code English
picoplatin [INN]
Common Name English
ZD0473
Code English
PICOPLATIN [MI]
Common Name English
NX-473
Code English
Classification Tree Code System Code
NCI_THESAURUS C1450
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
FDA ORPHAN DRUG 212305
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
EU-Orphan Drug EU/3/07/502
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
Code System Code Type Description
USAN
SS-50
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
SMS_ID
100000090660
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
INN
8205
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
WIKIPEDIA
PICOPLATIN
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
MERCK INDEX
m8787
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB04874
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
FDA UNII
B5TAN0L720
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
CAS
181630-15-9
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
ChEMBL
CHEMBL3544907
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
EVMPD
SUB29605
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
NCI_THESAURUS
C48416
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
PUBCHEM
177358
Created by admin on Sat Dec 16 16:59:59 UTC 2023 , Edited by admin on Sat Dec 16 16:59:59 UTC 2023
PRIMARY
Related Record Type Details
Structure of .ALPHA.-PICOLINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PICOPLATIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966